A method comprising: (a) measuring, in a biological sample obtained from a cancer patient with clear cell renal cell carcinoma, an expression level of at least one RNA transcript, or its expression product, of LMNB1; (b) normalizing the expression level to obtain a normalized expression level; and (c) (i) determining a likelihood of recurrence of cancer for the patient based on the normalized expression level of the at least one RNA transcript, or its expression product, of LMNB1, wherein the normalized expression levels of LMNB1 are positively correlated with a higher risk of cancer recurrence; or (ii) determining a likelihood of an increased tumor stage for the patient based on the normalized expression level of at least one RNA transcript, or its expression product, of LMNB1, wherein the normalized expression level of LMNB1 is positively correlated with increased stage of the tumour; or (iii) determining a likelihood of an increased tumour grade for the patient based on the normalized expression level of the RNA transcript, or its expression product, of LMNB1, wherein the normalized expression level of LMNB1 is positively correlated with increased grade of the tumour; or (iv) determining the presence of necrosis for the patient based on the normalized expression level of the RNA transcript, or its expression product, of LMNB1, wherein the normalized expression level of LMNB1 is positively correlated with the presence of necrosis. (a) measuring, in a biological sample obtained from a cancer patient with clear cell renal cell carcinoma, an expression level of at least one RNA transcript, or its expression product, of LMNB1; (b) normalizing the expression level to obtain a normalized expression level; and (c) (i) determining a likelihood of recurrence of cancer for the patient based on the normalized expression level of the at least one RNA transcript, or its expression product, of LMNB1, wherein the normalized expression levels of LMNB1 are positively correlated with a higher risk of cancer recurrence; or (ii) determining a likelihood of an increased tumor stage for the patient based on the normalized expression level of at least one RNA transcript, or its expression product, of LMNB1, wherein the normalized expression level of LMNB1 is positively correlated with increased stage of the tumour; or (iii) determining a likelihood of an increased tumour grade for the patient based on the normalized expression level of the RNA transcript, or its expression product, of LMNB1, wherein the normalized expression level of LMNB1 is positively correlated with increased grade of the tumour; or (iv) determining the presence of necrosis for the patient based on the normalized expression level of the RNA transcript, or its expression product, of LMNB1, wherein the normalized expression level of LMNB1 is positively correlated with the presence of necrosis. (i) determining a likelihood of recurrence of cancer for the patient based on the normalized expression level of the at least one RNA transcript, or its expression product, of LMNB1, wherein the normalized expression levels of LMNB1 are positively correlated with a higher risk of cancer recurrence; or (ii) determining a likelihood of an increased tumor stage for the patient based on the normalized expression level of at least one RNA transcript, or its expression product, of LMNB1, wherein the normalized expression level of LMNB1 is positively correlated with increased stage of the tumour; or (iii) determining a likelihood of an increased tumour grade for the patient based on the normalized expression level of the RNA transcript, or its expression product, of LMNB1, wherein the normalized expression level of LMNB1 is positively correlated with increased grade of the tumour; or (iv) determining the presence of necrosis for the patient based on the normalized expression level of the RNA transcript, or its expression product, of LMNB1, wherein the normalized expression level of LMNB1 is positively correlated with the presence of necrosis.